At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 101 enrolled
Drug / intervention
Mitomycin C +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)
In Brief
A Phase 3 clinical trial evaluating Mitomycin C and Gemcitabine for Urinary Bladder Neoplasms. Completed, enrolled 101 participants across 3 sites.
Detailed Summary
To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder Neoplasms
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionOct 2021
TodayJul 2026
First PostedMar 1, 2016
Enrollment StartApr 19, 2016
Primary CompletionOct 22, 2021
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 10.3 years ago
Interventions
Mitomycin Cdrug
Cancer chemotherapeutic agent
Gemcitabinedrug
Cancer chemotherapeutic agent